Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Biomedical/pharma

Biomedical/pharma, Oncology, Personal/public health, Public health, Women’s health

The rise of women’s health

It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?

Using real-world data for post-market surveillance of drug safety

After a therapeutic drug hits the market, it is crucial to continuously gather, analyze, and report data regarding its safety and potential side effects, a practice known as pharmacovigilance. Unlike clinical trials, this involves real-world data (RWD), presenting unique challenges in terms of both quality and quantity. The Belgian BELpREG project seeks to employ RWD for monitoring drug utilization during pregnancy and investigating potential safety implications for both maternal and child health. This initiative holds great promise, although it faces substantial hurdles on its path to success.

miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform

Muna Therapeutics: hopeful solutions for memory loss

Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones.

V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

Belgium needs boldness for healthcare innovation

This year, Science for health will explore the inspiring innovations at the interface of biology and technology. The event will bring together academics, industry leaders, and policymakers to explore the newest treatment platforms and factories of the future. BioVox spoke to Werner Verbiest, member of the event’s Scientific Committee, about the topic and why collaboration is so key right now.

Lean years for company creation in Europe?

After an exceptional sequence of socio-economic shocks over the past few years, the number of new companies being formed in key European biotech hubs has stalled. Early-stage investors need to roll up their sleeves and help to crank the engine of EU innovation back to life.

Hearts in space: a Belgian story of successful collaboration

AstroCardia has developed a heart-on-a-chip to study cardiovascular aging… in space! Trials will begin in 2025 aboard the International Space Station (ISS). The MEDVIA project was made possible thanks to the combined expertise of the five Belgian partners: Space Applications Services, the Belgian Nuclear Research Center (SCK CEN), QbD Group, BIO INX, and Antleron.

V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines

Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development.

V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases

Jan Rabaey on the convergence of biology and technology

Belgian Prof. Jan Rabaey has spent the past 35 years conducting pioneering tech research at the University of California at Berkeley. His groundbreaking electronics work has been used in a range of modern devices, including the iPad, brain-computer interfaces, and wireless sensor nodes used for the Internet of Things. The ongoing theme of his work has been miniaturization and connection, which he is now using to link technology and people like never before.

The obesity revolution: will new drugs bring about big changes?

The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are these treatments also leading to a shift in our perception of obesity? Obesity has long been seen as a failure of individual willpower, but it is becoming increasingly apparent that losing and keeping off the kilos is a more complex, biological challenge. These new drugs offer a first, rather simplistic solution to a complicated problem, yet perhaps they will lead to a much-needed revolution in how obesity is viewed and treated.

Advancing the pharmaceutical supply chain using artificial intelligence

Rapidly spreading diseases and unpredictable global shifts cause increased strain to the pharmaceutical supply chain, jeopardizing the secure delivery of drugs to those who are in need. Artificial intelligence can maximize efficacy of the value chain and allow optimal responses to changing market demands. Two experts share insights into the possibilities and hurdles associated with integration of machine learning tools into the pharmaceutical supply chain.

OHMX.bio: state-of-the-art omics solutions

OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.